FR2728169A1 - Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales - Google Patents

Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales Download PDF

Info

Publication number
FR2728169A1
FR2728169A1 FR9415255A FR9415255A FR2728169A1 FR 2728169 A1 FR2728169 A1 FR 2728169A1 FR 9415255 A FR9415255 A FR 9415255A FR 9415255 A FR9415255 A FR 9415255A FR 2728169 A1 FR2728169 A1 FR 2728169A1
Authority
FR
France
Prior art keywords
derivatives
use according
substance
composition
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9415255A
Other languages
English (en)
French (fr)
Other versions
FR2728169B1 (enExample
Inventor
Lacharriere Olivier De
Lionel Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
L'Oréal SA
Original Assignee
L'Oréal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L'Oréal SA filed Critical L'Oréal SA
Priority to FR9415255A priority Critical patent/FR2728169A1/fr
Priority to EP95402570A priority patent/EP0717998A1/fr
Priority to MX9505180A priority patent/MX9505180A/es
Priority to BR9505392A priority patent/BR9505392A/pt
Priority to AR33463795A priority patent/AR001060A1/es
Priority to RU95121083A priority patent/RU2135165C1/ru
Priority to HU9503622A priority patent/HU218946B/hu
Priority to JP07329299A priority patent/JP3078214B2/ja
Priority to CA002165519A priority patent/CA2165519C/fr
Priority to PL95311915A priority patent/PL311915A1/xx
Priority to US08/574,853 priority patent/US5730998A/en
Publication of FR2728169A1 publication Critical patent/FR2728169A1/fr
Application granted granted Critical
Publication of FR2728169B1 publication Critical patent/FR2728169B1/fr
Priority to JP2000102308A priority patent/JP2000309511A/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/14—Preparations for removing make-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR9415255A 1994-12-19 1994-12-19 Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales Granted FR2728169A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR9415255A FR2728169A1 (fr) 1994-12-19 1994-12-19 Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
EP95402570A EP0717998A1 (fr) 1994-12-19 1995-11-16 Utilisation d'un antagoniste de substance P pour le traitement des prurits, des algies oculaires et/ou palpébrales et des dysesthésies oculaires ou palpébrales
MX9505180A MX9505180A (es) 1994-12-19 1995-12-11 Uso de un antagonista de la substancia p para la obtencion de una composicion farmaceutica para el tratamiento de prurito y disestesias oculares o palpebrales.
BR9505392A BR9505392A (pt) 1994-12-19 1995-12-11 Utilizações de ao menos um antagonista de substância P
AR33463795A AR001060A1 (es) 1994-12-19 1995-12-15 Utilización de un antagonista de sustancia p para la preparación de una composición farmacéutica o dermatologica para tratar los pruritos y/o las algias oculares y/o palpebrales y/o las disestesias oculares o palpebrales
HU9503622A HU218946B (hu) 1994-12-19 1995-12-18 Stroncium (II) valamely szervetlen sója topikális alkalmazása szemviszketés, szem- és/vagy szemhéjfájdalmak és szem- és/vagy szemhéjérzékenység kezelésére alkalmas gyógyszerkészítmények előállítására
RU95121083A RU2135165C1 (ru) 1994-12-19 1995-12-18 Применение антагониста вещества р для лечения зуда, окулярных и/или пальпебральных болей, и окулярных или пальпебральных дизестезий
JP07329299A JP3078214B2 (ja) 1994-12-19 1995-12-18 そう痒症、目及び／又は瞼の痛み及び目もしくは瞼の知覚不全の治療のための拮抗剤物質ｐの使用
CA002165519A CA2165519C (fr) 1994-12-19 1995-12-18 Utilisation d'un antagoniste de substance p pour le traitement des prurits, des algies oculaires et/ou palpebrales et des dysesthesies oculaires ou palpebrales
PL95311915A PL311915A1 (en) 1994-12-19 1995-12-18 Pharmaceutic, dermatological and cosmetic composition
US08/574,853 US5730998A (en) 1994-12-19 1995-12-19 Use of a substance P antagonist for the treatment of pruritus, ocular and/or palpebral pain and ocular or palpebral dysaesthesia
JP2000102308A JP2000309511A (ja) 1994-12-19 2000-04-04 そう痒症、目及び／又は瞼の痛み及び目もしくは瞼の知覚不全の治療のための拮抗剤物質ｐの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9415255A FR2728169A1 (fr) 1994-12-19 1994-12-19 Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales

Publications (2)

Publication Number Publication Date
FR2728169A1 true FR2728169A1 (fr) 1996-06-21
FR2728169B1 FR2728169B1 (enExample) 1997-02-07

Family

ID=9469932

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9415255A Granted FR2728169A1 (fr) 1994-12-19 1994-12-19 Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales

Country Status (11)

Country Link
US (1) US5730998A (enExample)
EP (1) EP0717998A1 (enExample)
JP (2) JP3078214B2 (enExample)
AR (1) AR001060A1 (enExample)
BR (1) BR9505392A (enExample)
CA (1) CA2165519C (enExample)
FR (1) FR2728169A1 (enExample)
HU (1) HU218946B (enExample)
MX (1) MX9505180A (enExample)
PL (1) PL311915A1 (enExample)
RU (1) RU2135165C1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210015834A1 (en) * 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2738742B1 (fr) * 1995-09-19 1997-11-14 Oreal Utilisation d'au moins une eau thermale de vichy en tant qu'antagoniste de substance p
FR2742054B1 (fr) * 1995-12-06 1998-01-09 Synthelabo Compositions pharmaceutiques contenant un agent anti-inflammatoire et des ceramides vegetales
TW537894B (en) * 1998-05-26 2003-06-21 Novartis Ag A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist
EP1480678B1 (en) * 2002-02-13 2009-04-15 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
ES2329642B1 (es) * 2006-10-11 2010-06-08 Asac Compañia De Biotecnologia E Investigacion Sa Composicion farmaceutica hidratante.
US8426386B2 (en) 2006-10-16 2013-04-23 Lion Corporation NK1 receptor antagonist composition
CN107280991A (zh) * 2017-06-12 2017-10-24 上海宏度精细化工有限公司 一种卸妆用组合物及制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006099A1 (en) * 1991-09-16 1993-04-01 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
JPH05339240A (ja) * 1992-06-04 1993-12-21 Yamanouchi Pharmaceut Co Ltd テトラヒドロイソキノリンアミド誘導体
JPH06199892A (ja) * 1992-09-14 1994-07-19 Takeda Chem Ind Ltd Ｔａｎ−１６６６関連化合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5921656A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd ポリペプチド誘導体
US4472305A (en) 1983-05-17 1984-09-18 Sterling Drug Inc. Hexapeptide amides
US4839465A (en) 1987-01-20 1989-06-13 Sterling Drug Inc. Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof
GB8807921D0 (en) 1988-04-05 1988-05-05 Fujisawa Pharmaceutical Co Ws-9326 & its derivatives
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
GB8807246D0 (en) 1988-03-25 1988-04-27 Merck Sharp & Dohme Therapeutic agents
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
MX18467A (es) 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
FR2654726B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone et leur preparation.
FR2654725B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
UA41251C2 (uk) 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
EP0515681A4 (en) 1990-02-15 1993-12-29 Fujisawa Pharmaceutical Co., Ltd. Peptide compound
JPH0794439B2 (ja) 1990-05-31 1995-10-11 フアイザー・インコーポレイテツド 置換ピペリジンの製造法
JPH072740B2 (ja) 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド ３―アミノ―２―アリールキヌクリジン
ATE129409T1 (de) 1990-12-21 1995-11-15 Fujisawa Pharmaceutical Co Neue verwendung von peptidderivat.
CA2100163A1 (en) 1991-01-10 1992-07-11 John A. Lowe, Iii N-alkyl quinuclidinium salts
US5242930A (en) 1991-02-11 1993-09-07 Merck Sharp & Dohme Ltd. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
DE69200921T2 (de) 1991-03-01 1995-05-04 Pfizer 1-azabicyclo[3.2.2]nonan-3-aminderivate.
AU647592B2 (en) 1991-03-26 1994-03-24 Pfizer Inc. Stereoselective preparation of substituted piperidines
FR2677361A1 (fr) 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676442B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676447B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole et leur preparation.
FR2676443B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole et leur preparation.
FR2676446B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
RU2092486C1 (ru) 1991-05-22 1997-10-10 Пфайзер Инк. Замещенные 3-аминохинуклидины
GB9113219D0 (en) 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
SK282203B6 (sk) 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
TW202432B (enExample) 1991-06-21 1993-03-21 Pfizer
US5288730A (en) 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
AU664188B2 (en) 1991-07-05 1995-11-09 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
JPH06509087A (ja) 1991-07-05 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
US5495047A (en) 1991-07-10 1996-02-27 Merck, Sharp & Dohme (Ltd.) Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
CA2112397A1 (en) 1991-08-20 1993-03-04 Raymond Baker Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
JP2553020B2 (ja) 1991-11-07 1996-11-13 吉富製薬株式会社 キヌクリジン化合物およびその医薬用途
ES2111650T3 (es) * 1991-11-12 1998-03-16 Pfizer Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
WO1994026735A1 (en) * 1993-05-06 1994-11-24 Merrell Dow Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006099A1 (en) * 1991-09-16 1993-04-01 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
JPH05339240A (ja) * 1992-06-04 1993-12-21 Yamanouchi Pharmaceut Co Ltd テトラヒドロイソキノリンアミド誘導体
JPH06199892A (ja) * 1992-09-14 1994-07-19 Takeda Chem Ind Ltd Ｔａｎ−１６６６関連化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9404, Derwent World Patents Index; Class B02, AN 94-031791 *
DATABASE WPI Section Ch Week 9433, Derwent World Patents Index; Class B05, AN 94-269449 *
FOLKERS K ET AL: "SPANTIDE II, AN EFFECTIVE TACHYKININ ANTAGONIST HAVING HIGH POTENCY AND NEGLIGIBLE NEUROTOXICITY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 12, 1 June 1990 (1990-06-01), pages 4833 - 4835, XP000134336 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210015834A1 (en) * 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain

Also Published As

Publication number Publication date
US5730998A (en) 1998-03-24
HUT74745A (en) 1997-02-28
CA2165519A1 (fr) 1996-06-20
BR9505392A (pt) 1997-10-28
HU218946B (hu) 2001-01-29
RU2135165C1 (ru) 1999-08-27
CA2165519C (fr) 2002-07-16
JP3078214B2 (ja) 2000-08-21
EP0717998A1 (fr) 1996-06-26
PL311915A1 (en) 1996-06-24
FR2728169B1 (enExample) 1997-02-07
AR001060A1 (es) 1997-09-24
HU9503622D0 (en) 1996-02-28
JPH08208507A (ja) 1996-08-13
JP2000309511A (ja) 2000-11-07
MX9505180A (es) 1997-02-28

Similar Documents

Publication Publication Date Title
CA2165521C (fr) Composition topique contenant un antagoniste de substance p
EP0775492B1 (fr) Utilisation de sel de lanthanide, d'étain, de zinc, de manganèse, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
EP0734729B2 (fr) Utilisation d'un antagoniste de CGRP pour traiter les rougeurs cutanées d'origine neurogène et composition obtenue
EP0717997B1 (fr) Utilisation d'un antagoniste de substance P dans une composition pharmaceutique
CA2222311C (fr) Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
EP0722722B1 (fr) Utilisation d'un antagoniste de substance P pour le traitement des rougeurs cutanées d'origine neurogène
EP0716850B1 (fr) Utilisation d'un dérivé de l'éthylène diamine dans une composition cosmétique ou dermatologique et composition contenant notamment un produit à effet secondaire irritant
EP0734730B1 (fr) Utilisation d'un antagoniste de CGRP pour le traitement des prurits et des dysesthésies oculaires ou palpébraux
CA2165519C (fr) Utilisation d'un antagoniste de substance p pour le traitement des prurits, des algies oculaires et/ou palpebrales et des dysesthesies oculaires ou palpebrales
WO1997018799A1 (fr) Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
EP0737478B1 (fr) Utilisation de sel de métaux alcalino-terreux pour le traitement des prurits et des dysesthésies oculaires ou palpébraux
FR2732220A1 (fr) Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
FR2740342A1 (fr) Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
FR2732602A1 (fr) Utilisation d'un sel d'un metal alcalino-terreux dans une composition cosmetique ou pharmaceutique pour traiter les prurits
FR2732601A1 (fr) Utilisation d'un sel de metal alcalino-terreux pour le traitement des rougeurs cutanees d'origine neurogene
FR2732603A1 (fr) Utilisation d'un sel de strontium comme antagoniste de substance p

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20110831